SKYE — Skye Bioscience, Inc. Common Stock

Skye Bioscience, Inc. Common Stock (SKYE) is a biotechnology company listed on NASDAQ. It is led by Punit S. Dhillon B.A., based in 11250 El Camino Real, San Diego, CA, United States, 92130, with about 12 employees. Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Net income was -$12.8M. SKYE currently screens at market cap $25.0M.

Use this SKYE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SKYE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SKYE SEC filings page. Lician reads the product cache first so this HTML stays unique to Skye Bioscience, Inc. Common Stock even when a live quote feed is slow.